Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  American Journal of Gastroenterology

• Publication date

  1997-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 9219787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.

  1995cited by this paper
• 5-Aminosalicylic acid enemas to maintain remission in left-sided ulcerative colitis: a meta- and economic analysis.

  1995cited by this paper
• Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis

  1994cited by this paper
• 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.

  1994cited by this paper
• Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.

  1992cited by this paper
• Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.

  1992cited by this paper
• Combined therapy with 5-aminosalicylic tablets and enemas for maintaining remission in ulcerative colitis.

  1991cited by this paper
• Why do patients with ulcerative colitis relapse?

  1990cited by this paper
• Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis

  1990cited by this paper
• Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.

  1988cited by this paper
• 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis.

  1988cited by this paper
• Analyzing data from ordered categories.

  1984cited by this paper
• Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.

  1983cited by this paper
• Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis

  1982cited by this paper
• A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)

  1973cited by this paper
• Variation Between Observers in Describing Mucosal Appearances in Proctocolitis*

  1964cited by this paper
• Biopsy Studies in Ulcerative Colitis

  1956cited by this paper

• Morbus Crohn und Colitis ulcerosa

  2025cites this paper
• The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2)

  2024cites this paper
• Common Mistakes in Managing Patients with Inflammatory Bowel Disease

  2024cites this paper
• Update zur medikamentösen Therapie der Colitis ulcerosa

  2023cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009

  2023cites this paper
• Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study

  2022cites this paper
• Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α

  2022cites this paper
• Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

  2020cites this paper
• Aktualisierung der Colitis ulcerosa Leitlinie 2020

  2020influential citation
• Aktualisierung der Colitis-ulcerosa-Leitlinie 2020

  2020cites this paper
• Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.

  2020cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline

  2020cites this paper
• Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADE

  2020cites this paper
• Mesalamine in the Initial Therapy of Ulcerative Colitis.

  2020cites this paper
• Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis

  2020cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2020cites this paper
• GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach.

  2020cites this paper
• Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

  2020cites this paper
• Positioning therapies in ulcerative colitis.

  2020cites this paper
• Modern use of 5-aminosalicylic acid compounds for ulcerative colitis

  2020cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa

  2019cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa

  2019cites this paper
• AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

  2019cites this paper
• Comparative Efficacy and Tolerability of Pharmacological Agents for Management of Mild to Moderate Ulcerative Colitis: A Network Meta-analysis

  2019cites this paper
• Concepts in Inflammatory Bowel Disease Management

  2019cites this paper
• Maneuvering Clinical Pathways for Ulcerative Colitis

  2019cites this paper
• Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

  2019influential citation
• Evidence-based clinical practice guidelines for inflammatory bowel disease

  2018cites this paper
• The safety of beclomethasone dipropionate in the treatment of ulcerative colitis

  2018cites this paper
• Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.

  2018cites this paper
• Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

  2018influential citation
• Nonbiological therapeutic management of ulcerative colitis

  2018cites this paper
• American Gastroenterological Association Institute Guideline on the Management of Mild-Moderate Ulcerative Colitis

  2018cites this paper
• Adherence, risk factors of non-adherence and patient’s preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study

  2018cites this paper
• Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis

  2018cites this paper
• Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

  2017cites this paper
• Promises and Dangers of Combination Therapy

  2017cites this paper
• Second Korean guidelines for the management of ulcerative colitis

  2017cites this paper
• Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.

  2017cites this paper
• [Second Korean Guideline for the Management of Ulcerative Colitis].

  2017cites this paper
• Albumin as a prognostic marker for ulcerative colitis

  2017cites this paper
• An Update on Inflammatory Bowel Disease.

  2017cites this paper
• Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in Tuscany

  2016cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cites this paper
• Pathogenesis, Diagnosis, and Management of Ulcerative Proctitis, Chronic Radiation Proctopathy, and Diversion Proctitis

  2015cites this paper
• A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.

  2015cites this paper
• [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)].

  2015cites this paper
• Treatment of Distal/Left-Sided Ulcerative Colitis

  2014cites this paper
• Principles of Medical Management of Ulcerative Colitis

  2014cites this paper
• Current and emerging maintenance therapies for ulcerative colitis

  2014cites this paper
• Topical therapy is underused in patients with ulcerative colitis.

  2014cites this paper
• Maintenance of Remission in Ulcerative Colitis

  2014cites this paper
• Expert Review of Gastroenterology & Hepatology

  2013cites this paper
• Topical Therapy

  2013cites this paper
• Review article: strategies for the management of chronic unremitting ulcerative colitis

  2013cites this paper
• Ulcerative colitis: prevention of relapse

  2013cites this paper
• Ulcerative colitis.

  2013cites this paper
• Simulated Comparison of Topical and Oral Formulations of 5-Aminosalicylate for the Treatment of Ulcerative Colitis

  2013cites this paper
• Management and treatment of distal ulcerative colitis

  2013cites this paper
• ULCERATIVE COLITIS : CURRENT MANAGEMENT STRATEGY

  2012cites this paper
• Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?

  2012cites this paper
• [Guidelines for the management of ulcerative colitis].

  2012cites this paper
• Oral 5-aminosalicylic acid preparations in the treatment of ulcerative colitis

  2012cites this paper
• The Pharmacological Profile and Clinical Use of Mesalazine (5-Aminosalicylic Acid)

  2012cites this paper
• Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.

  2012cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2012cites this paper
• Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis

  2012cites this paper
• Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management

  2012cites this paper
• Improving Delivery of Aminosalicylates in Ulcerative Colitis

  2012cites this paper
• Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2012cites this paper
• Randomized controlled clinical trials in mild-moderate ulcerative colitis.

  2012cites this paper
• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

  2012cites this paper
• 궤양성 대장염 치료 가이드라인

  2012cites this paper
• [Topical therapy of ulcerative colitis].

  2011cites this paper
• Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

  2011cites this paper
• 5-ASAs in the Treatment of Inflammatory Bowel Disease

  2011cites this paper
• Optimization of conventional therapy in patients with IBD

  2011cites this paper
• Is 5-ASA still the treatment of choice for ulcerative colitis?

  2011cites this paper
• Review article: delivery and efficacy of topical 5‐aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis

  2011cites this paper
• Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 – Ergebnisse einer Evidenzbasierten Konsensuskonferenz

  2011cites this paper
• Medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis

  2011cites this paper
• Topische Therapie bei Colitis ulcerosa

  2011cites this paper
• [No best treatment for severe outbreaks: Maintenance, the key in colitis].

  2011cites this paper
• Conventional medical management of inflammatory bowel disease.

  2011cites this paper
• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

  2010cites this paper
• The Asia‐Pacific consensus on ulcerative colitis

  2010cites this paper
• Erratum: Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

  2010cites this paper
• Dose level and dosing method of steroids for moderate ulcerative colitis

  2010cites this paper
• Efficacy and safety of drugs for ulcerative colitis

  2010cites this paper
• A Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Mesalamine Suppositories 1 g at Bedtime and 500 mg Twice Daily in Patients with Active Mild-to-Moderate Ulcerative Proctitis

  2010cites this paper
• A Review of Delayed-Release MMX Mesalamine: It’s Use in the Treatment of Ulcerative Colitis

  2009cites this paper
• Therapeutic strategies for the management of ulcerative colitis

  2009cites this paper
• The Asia-Pacific Consensus on Ulcerative Colitis: AP Consensus UC

  2009cites this paper
• Crohn's and Colitis: Treatment of 5-ASA Responders

  2009cites this paper
• Advances In Inflammatory Bowel Diseases

  2009cites this paper
• Novel 5-aminosalicylic acid formulations in ulcerative colitis: old dog, new tricks.

  2008cites this paper
• MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis

  2008cites this paper
• What is the optimal maintenance treatment for ulcerative colitis?

  2008cites this paper